These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 24770611)

  • 21. MY APPROACH to the Patient With Memory Loss Who Needs a Statin.
    Watson KE; Sallam T
    Trends Cardiovasc Med; 2017 Feb; 27(2):158-159. PubMed ID: 28107839
    [No Abstract]   [Full Text] [Related]  

  • 22. Statin therapy for young adults: A long-term investment worth considering.
    Miedema MD; Nauffal VD; Singh A; Blankstein R
    Trends Cardiovasc Med; 2020 Jan; 30(1):48-53. PubMed ID: 30808553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statin safety: an overview and assessment of the data--2005.
    Bays H
    Am J Cardiol; 2006 Apr; 97(8A):6C-26C. PubMed ID: 16581330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol treatment and changes in guidelines in an academic medical practice.
    Schoen MW; Salas J; Scherrer JF; Buckhold FR
    Am J Med; 2015 Apr; 128(4):403-9. PubMed ID: 25460526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines.
    Martin SS; Sperling LS; Blaha MJ; Wilson PWF; Gluckman TJ; Blumenthal RS; Stone NJ
    J Am Coll Cardiol; 2015 Apr; 65(13):1361-1368. PubMed ID: 25835448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Guidelines for the management of dyslipidemia].
    Díaz Rodríguez Á;
    Semergen; 2014 Sep; 40 Suppl 4():19-25. PubMed ID: 25595349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.
    Finegold JA; Manisty CH; Goldacre B; Barron AJ; Francis DP
    Eur J Prev Cardiol; 2014 Apr; 21(4):464-74. PubMed ID: 24623264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin Toxicity.
    Ward NC; Watts GF; Eckel RH
    Circ Res; 2019 Jan; 124(2):328-350. PubMed ID: 30653440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin use and the risk of incident diabetes mellitus: a review of the literature.
    Colbert JD; Stone JA
    Can J Cardiol; 2012; 28(5):581-9. PubMed ID: 22658337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving long-term adherence to statin therapy: a qualitative study of GPs' experiences in primary care.
    Krüger K; Leppkes N; Gehrke-Beck S; Herrmann W; Algharably EA; Kreutz R; Heintze C; Filler I
    Br J Gen Pract; 2018 Jun; 68(671):e401-e407. PubMed ID: 29686133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.
    Maddox TM; Borden WB; Tang F; Virani SS; Oetgen WJ; Mullen JB; Chan PS; Casale PN; Douglas PS; Masoudi FA; Farmer SA; Rumsfeld JS
    J Am Coll Cardiol; 2014 Dec; 64(21):2183-92. PubMed ID: 25447259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
    Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
    Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of statin therapy.
    Adhyaru BB; Jacobson TA
    Nat Rev Cardiol; 2018 Dec; 15(12):757-769. PubMed ID: 30375494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence.
    Robinson JG; Stone NJ
    Eur Heart J; 2015 Aug; 36(31):2110-2118. PubMed ID: 25994746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.
    Naci H; Brugts J; Ades T
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):390-9. PubMed ID: 23838105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.